147 related articles for article (PubMed ID: 32652112)
1. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; Hackl W; Thuerlimann B; Viale G; Di Leo A; Colleoni M; Regan MM; Loi S
Ann Oncol; 2020 Oct; 31(10):1359-1365. PubMed ID: 32652112
[TBL] [Abstract][Full Text] [Related]
2. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
4. Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Guerini-Rocco E; Gray KP; Fumagalli C; Reforgiato MR; Leone I; Rafaniello Raviele P; Munzone E; Kammler R; Neven P; Hitre E; Jerusalem G; Simoncini E; Gombos A; Deleu I; Karlsson P; Aebi S; Chirgwin J; Di Lauro V; Thompson A; Graas MP; Barber M; Fontaine C; Loibl S; Gavilá J; Kuroi K; Müller B; O'Reilly S; Di Leo A; Goldhirsch A; Viale G; Barberis M; Regan MM; Colleoni M
Clin Cancer Res; 2021 Jan; 27(2):504-512. PubMed ID: 33082214
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
6. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
7. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
[TBL] [Abstract][Full Text] [Related]
8. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
9. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
10. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Zardavas D; Te Marvelde L; Milne RL; Fumagalli D; Fountzilas G; Kotoula V; Razis E; Papaxoinis G; Joensuu H; Moynahan ME; Hennessy BT; Bieche I; Saal LH; Stal O; Iacopetta B; Jensen JD; O'Toole S; Lopez-Knowles E; Barbaraeschi M; Noguchi S; Azim HA; Lerma E; Bachelot T; Wang Q; Perez-Tenorio G; Can de Velde CJH; Rea DW; Sabine V; Bartlett JMS; Sotiriou C; Michiels S; Loi S
J Clin Oncol; 2018 Apr; 36(10):981-990. PubMed ID: 29470143
[TBL] [Abstract][Full Text] [Related]
11. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L; Vingiani A; Garuti A; Vernieri C; Belfiore A; Agnelli L; Dagrada G; Ivanoiu D; Bonizzi G; Munzone E; Lippolis L; Dameri M; Ravera F; Colleoni M; Viale G; Magnani L; Ballestrero A; Zoppoli G; Pruneri G
PLoS Genet; 2023 Jan; 19(1):e1010563. PubMed ID: 36595552
[TBL] [Abstract][Full Text] [Related]
12. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
[TBL] [Abstract][Full Text] [Related]
14. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
Ogiya A; Yamazaki K; Horii R; Shien T; Horimoto Y; Masuda N; Inao T; Hosoda M; Ishida N; Osako T; Takahashi M; Endo Y; Miyoshi Y; Yasojima H; Tomioka N; Yamashita H;
Breast Cancer; 2017 May; 24(3):473-482. PubMed ID: 27628678
[TBL] [Abstract][Full Text] [Related]
15. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Dubsky P; Brase JC; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Fisch K; Kronenwett R; Gnant M; Filipits M;
Br J Cancer; 2013 Dec; 109(12):2959-64. PubMed ID: 24157828
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
[TBL] [Abstract][Full Text] [Related]
17. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
19. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
20. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
